< 5o3n4s
![endif]-->
Dr. Reddy’s Laboratories Ltd., today announced the launch of FXR™, a therapeutic equivalent generic version of Ocaliva® (obeticholic acid) in India, indicated for the treatment of Primary Biliary Cholangitis (PBC), in combination with Ursodeoxycholic Acid […]
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Desmopressin Acetate Injection USP, 4 mcg/mL Single-dose Ampules, a therapeutic […]
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Fenofibrate Tablets USP, a therapeutic equivalent generic version of Tricor® […]
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Naloxone Hydrochloride Injection USP, 2 mg/2 mL (1 mg/mL) Single-dose […]
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Bortezomib for Injection 3.5 mg/vial, approved by the U.S. Food […]
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Ramelteon Tablets, 8 mg, a therapeutically equivalent generic version of […]
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) announced positive topline results from its Phase 2b study of PPC-06 (formerly referred to as […]
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Testosterone Gel 1.62%, a therapeutic equivalent generic version of AndroGel® […]
Copyright © 2022 | Business News This Week
